GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

NCT Number	NCT07297667
Lead Sponsor	Canadian Cancer Trials Group Collaborators: University of Calgary, Canadian Institutes of Health Research (CIHR), BioCanRx
Conditions	Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
Enrollment	30 participants
Start Date	2026-07-30
Primary Completion	2028-12-01 (estimated)
Study Completion	2033-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-12